M&A Deal Summary |
|
|---|---|
| Date | 2007-02-01 |
| Target | Syntonix Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Biogen |
| Sellers(s) |
Alta Partners
Bay City Capital |
| Deal Type | Add-on Acquisition |
| Deal Value | 120M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1978 |
| Sector | Life Science |
| Employees | 7,605 |
| Revenue | 9.7B USD (2024) |
Biogen is a biopharmaceutical company focused on discovering, developing, and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen was founded in 1978 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 9 |
| Sector (Life Science) | 2 of 9 |
| Type (Add-on Acquisition) | 2 of 7 |
| State (Massachusetts) | 1 of 2 |
| Country (United States) | 1 of 6 |
| Year (2007) | 1 of 1 |
| Size (of disclosed) | 7 of 8 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-05-31 |
Fumapharm AG
Luzern, Switzerland Fumapharm is a privately held pharmaceutical company headquartered in Lucerne, Switzerland. FUMADERM, an oral product containing fumaric acid esters, was approved in Germany in 1994 where it is the leading prescription for oral systemic treatment of severe psoriasis. Fumedica GmbH distributes FUMADERM in Germany. |
Buy | $761M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-02-14 |
Stromedix
Cambridge, Massachusetts, United States Stromedix, Inc., is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrosis and organ failure. Stromedix's investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and Frazier Healthcare. |
Buy | $562M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 33 of 85 |
| Sector (Life Science) | 22 of 65 |
| Type (Add-on Acquisition) | 22 of 45 |
| State (Massachusetts) | 1 of 8 |
| Country (United States) | 28 of 75 |
| Year (2007) | 2 of 6 |
| Size (of disclosed) | 20 of 23 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-02-01 |
Arrow Therapeutics
London, United Kingdom Arrow Therapeutics utilizes its genome-based target discovery technology to search for novel anti-microbial compounds. The Company is focused on unexplored targets for antibiotics, anti-viral, and anti-fungal therapies and aims to overcome the rapidly growing problem of microbial resistance. |
Sell | $150M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-03-14 |
Netli
Mountain View, California, United States Netli is the first service provider to deliver a business-quality Internet. Netli addresses the limitations of the Internet and enables customers to transparently extend the reach of their Web-enabled enterprises without distributing complex applications or paying for costly additional infrastructure |
Sell | $178M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 22 of 63 |
| Sector (Life Science) | 15 of 46 |
| Type (Add-on Acquisition) | 10 of 31 |
| State (Massachusetts) | 2 of 9 |
| Country (United States) | 21 of 60 |
| Year (2007) | 1 of 4 |
| Size (of disclosed) | 12 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-01 |
NextWave Pharmaceuticals
Cupertino, California, United States NextWave Pharmaceuticals is a specialty pharmaceutical company developing extended release OTC and prescription products for children and adults. NextWave Pharmaceuticals was founded in 2005 and is based in Cupertino, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-03-01 |
Itamar Medical
Caesarea, Israel Itamar Medical is a medical device company which develops, markets and sells diagnostic medical devices based on the PAT™ (Peripheral Arterial Tone) signal. The PAT signal is a non-invasive "window" to the cardiovascular system and the autonomic nervous system. Itamar Medical was founded in 1997 and is based in Caesarea, Israel. |
Sell | - |
